Neurizon advances NUZ-001 ALS trial into treatment extension

Neurizon Therapeutics has advanced its Phase 2/3 HEALEY ALS Platform Trial of NUZ-001, with the first participant completing the 36-week randomised phase and entering the Active Treatment Extension (ATE).

The milestone moves Regimen I into its longer-term treatment phase, where eligible participants can receive investigational NUZ-001 regardless of their original treatment allocation.

The study is evaluating NUZ-001 in 250 people with amyotrophic lateral sclerosis (ALS) across 78 clinical sites in the US. Topline results from the randomised controlled trial (RCT) phase are expected in late Q2 2027.

The extension will provide additional information about the safety, tolerability and potential effects of longer-term treatment, although it is not a separate controlled assessment of efficacy.

Longer-term assessment of NUZ-001

Participants entering the optional 36-week extension will receive NUZ-001 and continue regular clinical and safety assessments.

These will include measurements of functional decline using the ALS Functional Rating Scale-Revised (ALSFRS-R), respiratory function and quality of life.

Blood and urine biomarkers, including neurofilament light chain (NfL), will also be assessed throughout the extension.

The additional observations are intended to complement the randomised trial dataset and contribute to the wider clinical evidence supporting NUZ-001’s development.

Treatment assignments will remain blinded during the extension.

Neurizon CEO Chris Bremer said: “The first participant entering the Active Treatment Extension is an important milestone for Regimen I and reflects the continued progress of our clinical development program.

“For people living with ALS, a progressive disease with limited treatment options, advancing research into potential new therapies is critically important. We are grateful to the participants who continue to contribute to this research, and to their families and clinical teams for their commitment.”

FDA feedback offers potential regulatory pathway

The announcement follows written feedback from the US Food and Drug Administration (FDA), which indicated that positive results from the HEALEY ALS Platform Trial could support a traditional approval pathway for NUZ-001.

The agency also indicated that Regimen I may potentially serve as a single registrational study supporting a New Drug Application (NDA), subject to the results and confirmatory evidence meeting applicable regulatory requirements.

This is a potentially significant development for Neurizon, although the FDA feedback does not constitute approval or guarantee that the trial will be sufficient to support an application.

Regimen I completed enrolment of 250 participants in July 2026, with recruitment taking approximately five months across 78 activated US clinical sites.

Results expected in 2027

The HEALEY ALS Platform Trial is being conducted in collaboration with the Healey & AMG Center for ALS at Mass General Brigham.

Participants were randomised in a 3:1 ratio to receive NUZ-001 or placebo during the 36-week RCT phase, followed by an optional 36-week active treatment extension.

The primary evaluation combines functional decline, measured using ALSFRS-R, and survival.

Merit Cudkowicz, executive director of the Mass General Brigham Neuroscience Institute and director of the Healey & AMG Center for ALS, said: “After enrolling 250 participants in 5 months, we are excited to now have taken this next step in Regimen I of the HEALEY ALS Platform Trial.”

Neurizon expects topline results from the randomised phase in late Q2 2027. These findings will inform further discussions with the FDA and other regulatory authorities about the potential development and approval pathway for NUZ-001.

Mail Icon

news via inbox

Sign up for our newsletter and get the latest news right in your inbox